Earnings call transcript: L’Oréal Q1 2026 shows strong growth amid IT challenges

L’Oréal reported Q1 like-for-like growth of 7.6%, or 6.7% adjusted for IT transformation impacts, outperforming the beauty market’s roughly 3.8% growth. Professional, Luxury, and Dermatological Beauty were standout areas, with China stabilizing at about 1%-2% growth and Europe and the U.S. both showing strong momentum. Management flagged EUR 90 million-EUR 100 million of potential added cost from oil/tariffs and a 90 bp IT drag, but reiterated confidence in full-year growth and margin protection.

Analysis

The setup is better for the premium end of beauty than the headline market implies. When selective and dermo are taking share in China while Europe remains resilient, the key second-order effect is that mix is improving even if unit growth moderates; that supports pricing power and offsets some tariff/oil leakage. The biggest winner is not the market leader per se, but brands with enough innovation cadence to keep consumers trading up despite a softer macro backdrop.

The operational drag from the IT transition matters more for near-term sell-side estimates than for franchise value. A few hundred basis points of timing noise can mask true momentum, and that creates an opportunity in names where investors over-penalize reported growth while the underlying sell-out is accelerating. The more important risk is a compounding effect in the U.S.: if inventory prebuilds ahead of systems migration coincide with freight/oil inflation, reported margins can look worse for 1-2 quarters even if demand stays intact.

The market is underappreciating how much of the growth story is being pulled by channels and categories that are less cyclical than discretionary beauty at first glance: premium haircare, dermo, and prestige fragrance. That tends to compress volatility in the earnings stream and should support multiple durability. The main contrarian risk is that consensus is extrapolating a China rebound too quickly; if the selective premium recovery stalls, the mix tailwind fades and the stock can de-rate even with decent top-line growth. For peers, the Kering beauty transition is more of a medium-term competitive threat than an immediate earnings driver, but it increases the odds of portfolio reshuffling and more aggressive licensing competition across fragrance and luxury skincare.

Key Decisions for Investors

• Stay long L’Oréal vs. Coty into the next 1-2 quarters: the mix shift toward premium/dermo and better China selective demand should keep relative growth and margin quality ahead; use any post-earnings pullback on IT-transition noise to add.
• Short COTY on a 3-6 month horizon against a long basket of premium beauty leaders: weaker brand equity and less pricing flexibility make it more exposed if fragrance growth normalizes and channel mix becomes less favorable.
• Pair long L’Oréal / short Unilever for 1H26: L’Oréal has more direct leverage to premium beauty demand, while Unilever’s broader consumer exposure leaves it more vulnerable if oil-driven input inflation forces pricing tradeoffs.
• Buy 3-6 month downside puts on L’Oréal only on strength if the stock rerates into reported 'clean-up' growth: the best risk/reward is to fade complacency around China and the U.S. IT migration once the market has priced in the sell-out resilience.